Browse > Article
http://dx.doi.org/10.4014/jmb.2204.04041

Isolation and Characterization of Engineered Nucleoside Deoxyribosyltransferase with Enhanced Activity Toward 2'-Fluoro-2'-Deoxynucleoside  

Yoo, Yeon-Jin (Department of Biological Sciences and Bioengineering, Inha University)
Choi, Kang-Hyun (Department of Biological Sciences and Bioengineering, Inha University)
Kim, Byoung-Kyun (Division of Bioprocess Discovery, ST Pharm)
Choi, Si-Sun (Department of Biological Sciences and Bioengineering, Inha University)
Kim, Eung-Soo (Department of Biological Sciences and Bioengineering, Inha University)
Publication Information
Journal of Microbiology and Biotechnology / v.32, no.8, 2022 , pp. 1041-1046 More about this Journal
Abstract
Nucleoside deoxyribosyltransferase (NDT) is an enzyme that replaces the purine or pyrimidine base of 2'-deoxyribonucleoside. This enzyme is generally used in the nucleotide salvage pathway in vivo and synthesizes many nucleoside analogs in vitro for various biotechnological purposes. Since NDT is known to exhibit relatively low reactivity toward nucleoside analogs such as 2'-fluoro-2'-deoxynucleoside, it is necessary to develop an enhanced NDT mutant enzyme suitable for nucleoside analogs. In this study, molecular evolution strategy via error-prone PCR was performed with ndt gene derived from Lactobacillus leichmannii as a template to obtain an engineered NDT with higher substrate specificity to 2FDU (2'-fluoro-2'-deoxyuridine). A mutant library of 214 ndt genes with different sequences was obtained and performed for the conversion of 2FDU to 2FDA (2'-fluoro-2'-deoxyadenosine). The E. coli containing a mutant NDT, named NDTL59Q, showed 1.7-fold (at 40℃) and 4.4-fold (at 50℃) higher 2FDU-to-2FDA conversions compared to the NDTWT, respectively. Subsequently, both NDTWT and NDTL59Q enzymes were over-expressed and purified using a His-tag system in E. coli. Characterization and enzyme kinetics revealed that the NDTL59Q mutant enzyme containing a single point mutation of leucine to glutamine at the 59th position exhibited superior thermal stability with enhanced substrate specificity to 2FDU.
Keywords
Nucleoside deoxyribosyltransferase; 2'-fluoro-2'-deoxynucleoside; error-prone PCR; specificity; enzyme kinetics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Crooke ST, Baker BF, Crooke RM, Liang, X-H. 2021. Antisense technology: an overview and prospectus. Nat. Rev. Drug. Discov. 20: 427-453.   DOI
2 Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. 2020. Antisense oligonucleotides: an emerging area in drug discovery and development. J. Clin. Med. 9: 2004.   DOI
3 Xiong H, Veedu RN, Diermeier SD. 2021. Recent advances in oligonucleotide therapeutics in oncology. Int. J. Mol. Sci. 22: 3295.   DOI
4 Munch-Petersen. 1983. Metabolism of nucleotides, nucleosides and nucleobases in microorganisms. Academic Press Inc. 203-258.
5 Cadwell RC, Joyce GF. 1992. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2: 28-33.   DOI
6 Danzin C, Cardinaud R. 1976. Deoxyribosyl transfer catalysis with trans-N-deoxyribosylase. Eur. J. Biochem. 62: 365-72.   DOI
7 Roush AH, Betz RF. 1958. Purification and properties of trans-N-deoxyribosylase. J. Biol. Chem. 233: 261-266.   DOI
8 Cardinaud R, Holguin J. 1979. Nucleoside deoxyribosyltransferase-II from Lactobacillus helveticus substrate specificity studied. Pyrimidine bases as acceptors. Biochim. Biophys. Acta 568: 339-347.   DOI
9 Danzin C, Cardinaud R. 1974. Deoxyribosyl transfer catalysis with trans-N-deoxyribosylase. Eur. J. Biochem. 48: 255-262.   DOI
10 Lysik MA, Wu-Pong S. 2003. Innovations in oligonucleotide drug delivery. J. Pharm. Sci. 92: 1559-1573.   DOI
11 Liu P, Sharon A, Chu CK. 2008. Fluorinated nucleosides: synthesis and biological implication. J. Fluor. Chem. 129: 743-766.   DOI
12 Wilson DS, Keefe AD. 2001. Random mutagenesis by PCR. Curr. Protoc. Mol. Biol. Chapter 8: unit 8.3.
13 Wilds CJ, Damha MJ. 2000. 2'-Deoxy-2'-fluoro-beta-D-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic. Acids Res. 28: 3625-3635.   DOI
14 Chan JHP, Lim S, Wong WSF. 2006. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 33: 533-540.   DOI
15 Ochoa S, Milam VT. 2020. Modified nucleic acids: expanding the capabilities of functional oligonucleotides. Molecules 25: 4659.   DOI
16 McKenzie LK, El-Khoury R, Thorpe JD, Damha MJ, Hollenstein M. 2021. Recent progress in non-native nucleic acid modifications. Chem. Soc. Rev. 50: 5126-5164.   DOI
17 Manoharan M. 1999. 2'-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta. 1489: 117-130.   DOI